Tag: key

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Calix, Inc. (“Calix” or the “Company”) (NYSE:CALX) investors of the July 27, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Ear Health Market size & share revenue was valued at approximately USD 10.12 Billion in 2025 and is expected to reach USD 10.82 Billion in 2026 and is expected to reach around USD 16.87 Billion by 2035, at a CAGR of 5.7% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Sonova Holdings AG, GN Store Nord A/S, William Demant Holdings A/S, Starkey Laboratories Inc., WS Audiology, Cochlear Limited, MED-EL, Eargo Inc., Audina Hearing Instruments Inc., Rion Co. Ltd and others.

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Fluorescent In Situ Hybridization Probe Market size & share revenue was valued at approximately USD 1.14 Billion in 2025 and is expected to reach USD 1.23 Billion in 2026 and is expected to reach around USD 2.27 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientific Inc., Abbott Laboratories, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Bio-Rad Laboratories Inc., Oxford Gene Technology (Sysmex), Abnova Corporation, Empire Genomics LLC, MetaSystems Group and others.

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- National Healthcare Properties, Inc. (Nasdaq: NHP / NHPAP / NHPBP) (the “Company”), a self-managed real estate investment trust focused on acquiring, owning and investing in a diversified portfolio of healthcare real estate, with an emphasis on providing senior housing to serve a growing elderly population in the United States, today announced the preliminary results of its concurrent but separate offers to purchase up to a maximum aggregate purchase price in cash of $100 million of (i) its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (the “Series A Shares”), and (ii) its 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (the “Series B Shares,” and together with the Series A Shares, the “Shares”), in each case for a purchase price of $22.50 per share in cash (collectively, the “Offers”), each less any applicable withholding taxes and without interest. The Offers each expired at 5:00 p.m., New York City time, on June 16, 2026 (the “Expiration Date”).